Tag: thrombosis-related deaths
-
Possible Andexxa Recall After FDA Does Not Approve the Anticoagulant Reversal Drug in December 2024
AstraZeneca Says “while discussions with the FDA are ongoing, Andexxa will remain on the US market.” (Posted by Tom Lamb at Drug Injury Watch) In our November 21, 2024, article, “Do Andexxa Risks Outweigh Benefits Given Increased…
-
Do Andexxa Risks Outweigh Benefits Given Increased Rate of Thrombosis and Thrombosis-Related Deaths?
Issue to be Considered by FDA Advisory Committee on November 21, 2024, and Discussion May Lead to Andexxa Drug Recall (Posted by Tom Lamb at Drug Injury Watch) At its November 21, 2024 meeting, the FDA’s Cellular,…